已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Cefepime–Taniborbactam in Complicated Urinary Tract Infection

头孢吡肟 医学 美罗培南 菌血症 泌尿系统 随机化 人口 铜绿假单胞菌 随机对照试验 B组 外科 内科学 头孢他啶 微生物学 抗生素 抗生素耐药性 生物 遗传学 环境卫生 细菌
作者
Florian Wagenlehner,Leanne B. Gasink,Paul C. McGovern,Greg Moeck,Patrick McLeroth,MaryBeth Dorr,Aaron Dane,Tim Henkel
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:390 (7): 611-622 被引量:39
标识
DOI:10.1056/nejmoa2304748
摘要

BackgroundCarbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor combination with activity against Enterobacterales species and P. aeruginosa expressing serine and metallo-β-lactamases.MethodsIn this phase 3, double-blind, randomized trial, we assigned hospitalized adults with complicated urinary tract infection (UTI), including acute pyelonephritis, in a 2:1 ratio to receive intravenous cefepime–taniborbactam (2.5 g) or meropenem (1 g) every 8 hours for 7 days; this duration could be extended up to 14 days in case of bacteremia. The primary outcome was both microbiologic and clinical success (composite success) on trial days 19 to 23 in the microbiologic intention-to-treat (microITT) population (patients who had a qualifying gram-negative pathogen against which both study drugs were active). A prespecified superiority analysis of the primary outcome was performed after confirmation of noninferiority.Download a PDF of the Research Summary.ResultsOf the 661 patients who underwent randomization, 436 (66.0%) were included in the microITT population. The mean age of the patients was 56.2 years, and 38.1% were 65 years of age or older. In the microITT population, 57.8% of the patients had complicated UTI, 42.2% had acute pyelonephritis, and 13.1% had bacteremia. Composite success occurred in 207 of 293 patients (70.6%) in the cefepime–taniborbactam group and in 83 of 143 patients (58.0%) in the meropenem group. Cefepime–taniborbactam was superior to meropenem regarding the primary outcome (treatment difference, 12.6 percentage points; 95% confidence interval, 3.1 to 22.2; P=0.009). Differences in treatment response were sustained at late follow-up (trial days 28 to 35), when cefepime–taniborbactam had higher composite success and clinical success. Adverse events occurred in 35.5% and 29.0% of patients in the cefepime–taniborbactam group and the meropenem group, respectively, with headache, diarrhea, constipation, hypertension, and nausea the most frequently reported; the frequency of serious adverse events was similar in the two groups.ConclusionsCefepime–taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a safety profile similar to that of meropenem. (Funded by Venatorx Pharmaceuticals and others; CERTAIN-1 ClinicalTrials.gov number, NCT03840148.) Quick Take Cefepime–Taniborbactam for Complicated UTI 2m 19s
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
oligo完成签到 ,获得积分10
3秒前
8秒前
9秒前
xx完成签到 ,获得积分10
12秒前
13秒前
Jing发布了新的文献求助10
13秒前
zephyr发布了新的文献求助30
14秒前
Akim应助zjgjnu采纳,获得10
17秒前
漂亮白枫发布了新的文献求助10
17秒前
hug完成签到,获得积分0
20秒前
搜集达人应助Johnny采纳,获得30
21秒前
Hyh_orz应助sean采纳,获得50
23秒前
WuYiHHH发布了新的文献求助10
23秒前
bkagyin应助漂亮白枫采纳,获得10
23秒前
油条完成签到,获得积分10
27秒前
28秒前
30秒前
wanci应助调皮秋采纳,获得10
31秒前
32秒前
酷波er应助zzz采纳,获得10
33秒前
斐嘿嘿发布了新的文献求助10
34秒前
Johnny发布了新的文献求助30
34秒前
十四发布了新的文献求助10
36秒前
Cruffin完成签到 ,获得积分10
37秒前
zephyr完成签到,获得积分10
37秒前
38秒前
负责怀莲发布了新的文献求助10
38秒前
义气芷蝶完成签到 ,获得积分10
42秒前
yaling完成签到,获得积分10
43秒前
zzz发布了新的文献求助10
44秒前
44秒前
苗条世德完成签到,获得积分10
45秒前
怕孤独的元风完成签到,获得积分10
45秒前
Owen应助feng采纳,获得10
46秒前
斐嘿嘿完成签到,获得积分10
46秒前
47秒前
万能图书馆应助十四采纳,获得10
47秒前
Newt发布了新的文献求助10
48秒前
49秒前
oldblack完成签到,获得积分10
50秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989857
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255679
捐赠科研通 3270758
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882195
科研通“疑难数据库(出版商)”最低求助积分说明 809208